Association of Diabetes Mellitus and Clozapine : A Case Report by Bhat, Amritha et al.
INDIAN JOURNAL Of PSYCHIATRY. 2003. 45(1). 62-63 
Association of Diabetes Mellitus and 
Clozapine : A Case Report 
AMRITHA BHAT S, ANTHONY A. DINESH, ASHOK M.V., SUNITHA SIMON 
KURPAD & GANAPATHI.B. 
ABSTRACT 
A case of Paranoid Schizophrania who developed Type 2 diabetes mellitus while on 
treatment with clozapine, is described. A brief review of literature is provided. In this 
case, Clozapine therapy could have caused the diabetes, or accelerated a pre-existing 
process.This report aims to highlight the importance of monitoring for hyperglycemia, 
an adverse effect of clozapine, which is being increasingly recognized in recent times. 
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There are increasing reports of use of 
newer antipsychotics being associated with 
diabetes mellitus (Dan ct al., 2001). We 
report one such case and provide a brief 
review of literature. 
CASE 
Mr.X, a 25 year old male, with history of type 
2 diabetes mellitus (DM) in the mother, presented 
to us in 1992 with a three month history of 
delusions of persecution and reference, thought 
broadcast, and third person auditory hallucinations. 
He was diagnosed as having paranoid 
schizophrenia and given typical neuroleptics. 
Response to treatment was poor and his symptoms 
persisted despite receiving F.O'. In 1999, he was 
starred on clozapine following a serious suicidal 
attempt. At the time of initiating clozapine therapy, 
his weight was 69 kgs, bodv mass index (BMJ) 
23.9, and random blcxxi sugar (RBS) 152 mg/dl. 
In six months, he had improved. Three months 
after clozapine was started, RBS was 190 mg/dl and 
he was advised diet control and exercises. However, 
two months later, RBS was 401 mg/dl and oral 
hypoglycemics were prescribed. With this, he did 
well for more than a year. 
Four months ago, he had recurrence of psychotic 
symptoms. Compliance with both clozapine and 
oral hypoglycemics was questionable. His weight 
was 80.4 kg, BM1 27.8 and his blood sugars were 
elevated (Fasting Blood Sugar-168 mg/dl, Post 
Prandial Blood Sugar-211 mg/dl). 
The doses of clozapine and oral hypoglycemics 
were titrated. Over two weeks, his psychotic 
symptoms improved while his blood sugars 
normalized. 
DISCUSSION 
Impaired glucose metabolism was first 
described in psychotic patients even before 
the introduction of antipsychotics. The 
hypotheses put forward to explain this 
association were: circulating insulin antago-
nists (Schimmclbusch ct al., 1971), 
maternal zinc deficiency (Andrews, 1992) 
and an immunological explanation 
(Holden, 1999). Whether the onset of 
DM in our patient was before or after 
the introduction of clozapine is unfortu-
nately not clear, as at the time of his 
1CU admission for intermediate syndrome 
secondary to consumption of an 
organophosphorous compound, his el-
evated blood sugars were not followed 
up. It could be that the elevated RBS at 
that time was considered a transient 
phenomenon like stress hyperglycemia 
and the onset of DM was actually after 
clozapine was started. The other possibil-
ity is that the patient already had early 
DM, which worsened after use of 
clozapine. This could have been ascer-
tained had a glycosylated haemoglobin 
level been done. 
Newer antipsychotic medications are 
associated with occurrence of hyperglycemia, 
new onset type 2 DM, exacerbation of 
existing diabetes and diabetic ketoacidosis. 
Hyperglycemia is more frequently reported 
with chlorpromazine, clozapine, and is also 
seen with risperidone and quetiapine. 
TABLE I: Mechanism of action of 
impaired glucose metabolism caused 
by antipsychotics 
1. Interfering with beta cell insulin se-
cretion. Decrease pancreatic beta cell 
responsiveness to blood sugar levels 
because of antagonism to 5HT 1 A 
receptors. 
2. Increasing insulin resistance. 
• Increase appetite and calorie intake. 
• Changes in the distribution of body 
fat. 
• Decreased oxidative metabolism in 
tissues. 
• Interferes with insulin action cas-
cade. 
• Increased counter regulatory hor-
mones. 
• Increased free fatty acid release 
from adipose tissues. 
There may be a causal relationship 
between clozapine and the development 
or worsening of diabetes; onset of 
hyperglycemia may be rapid and severe 
(within six months of initiation of therapy) 
as was seen in our patient. Association is 
not dose dependent and risk does not end 
with extended use (Koller ct al., 2001). 
If our patient already had diabetes, tiSen 
clozapine could have just worsened it. 
Recent controlled studies have shown 
that clozapine and olanzapine have adverse 
effects on glucose metabolism independent 
of adiposity (David et al., 2000). The odds 
of being pre-obese or obese are nine times 
more in the psychiatrically ill than control 
subjects (Simon Kurpad ct al., 2001). Our 
patient was normal as shown by the BMI 
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before he starred taking clozapine, but 
has moved into the prc-obesc range after 
starting clozapine. 
All the studies mentioned highlight 
the role of antipsychotics in the devel-
opment of diabetes. However, we found 
no studies on the impact of diabetes on 
the course and outcome of schizophrenia. 
This needs further examination. 
For patients with known risk factors 
for diabetes, it is recommended that 
weight, plasma glucose and lipid levels be 
monitored quarterly for the first year and 
annually thereafter. For those without 
risk factors, it is felt that monitoring the 
same ever)' year after the age of 45 years 
is sufficient (Dan et al., 2(X)1). 
However, it should be borne in mind 
diat monitoring is to be tailored to the 
needs of an individual patient. We would 
recommend more frequent monitoring, 
especially given the rapid onset/worsen-
ing of diabetes in the case under discus-
sion. 
Also, treatment options in these pa-
tients have to be individualized. The 
continuation of clozapine requires clinical 
judgement and informed discussions with 
the patient and family members. 
CONCLUSION 
Clozapine is perhaps the best option 
in treatment resistant schizophrenia. 
Monitoring for agranulocytosis and sei-
zure risk has become a part of clinical 
practice. In this patient, clozapine was 
started at a time when its association with 
DM was not clear. There is now an 
emerging consensus on the need to 
monitor for other complications like 
DM. 
Clozapine is often used in very ill 
patients and such patients may not volun-
tarily report symptoms of diabetes mellitus 
like polydipsia. Further polydipsia is not 
uncommon in chronic schizophrenic 
patients.(Leon et al.,1994). Clinicians need 
to have a high index of suspicion and 
recognize diabetes mellitus early in patients 
on clozapine. 
REFERENCES 
Andrews R.C. (1992) Diabetes and schizophre-
nia: genes or zinc deficiency? Lancet, 340 
(8828). 1160. 
Dan WH, John W.N. (2001) Hyperglycemia 
and antipsychotic medications. J.Clin. Psychiatry, 
62 (supp 27), 15-26. 
David C.H. (2000) Clinical experience with 
insulin resistance.DKA, Type 2 DM in patients 
treated with atypical antipsychotic agents. 
J.CIinc.Psychiatry, 62(supp 27), 10-14. 
Holden R.J, Pakula I.S. (1999) The link 
between diabetes and schizophrenia: an immu-
nological explanation. Aust.New Zealand 
J.Psychiatry, 33 (2): 286-287. 
Koller E, Bruce S, Katherine B, Greg, D. 
(2001) Clozapine associated diabetes. Am.J.Med., 
Ill, 716-723. 
Leon j, Verghese C, Tracy J.I, Josissen R.C, 
Simpson CM. (1994) Polydipsia and water 
intoxication in psychiatric patients: a review, of 
the epidemiological literature." Biol Psychiatry, 35 
(6), 408-419. 
Schimmelbusch W.H, Mueller P.S, Sheps J. 
(1971) The positive correlation between insulin 
resistance and duration of hospitalization in 
untreated Schizophrenia. Brit.J. Psychiatry, I 18, 
429-436. 
Simon Kurpad Sunita, Himanshu Tandon, 
K.Srinivasan (2001) Prevalence of obesity among 
psychiatrically ill patients. Ind. J. Psychiatry, 
43(2), 138-146. 
*AMRITHA BHAT.S., M.B.B.S., Post graduate, ANTHONY A. DINESH, M.B.B.S. Post graduate, ASHOK M.V., M.D., Associate Professor, SUNITHA SIMON 
KURPAD, MRCPsych DNB Associate Professor, Department of Psychiatry, GANPATHI, B., M.D., D.M., D.N.B.. Associate Professor, Department of Medicine, 
St-John's Medical College, Bangalore. 
* Correspondence 
(63) 